Biotech Fund Sells Erasca Stake After 700% Rally
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 18 2026
0mins
Source: Yahoo Finance
- Share Reduction Details: Paradigm Biocapital Advisors disclosed the sale of 3,766,393 shares of Erasca in Q1 2026, valued at approximately $44.52 million, indicating a cautious approach to market volatility.
- Holding Proportion Change: Following this sale, Paradigm's stake in Erasca now represents 3.44% of its 13F AUM, reflecting a relative decline in importance within its portfolio and suggesting a reallocation towards other investments.
- Stock Performance: As of May 14, 2026, Erasca shares were priced at $10.37, marking a remarkable 716.5% increase over the past year, significantly outperforming the S&P 500 by 689.24 percentage points, demonstrating strong market confidence in its potential products.
- Investment Risk Advisory: Despite promising early clinical trial results, a recent incident involving a patient death led to a 46% drop in stock price in a single day, highlighting the high-risk nature of biotech investments and the need for investors to carefully assess timing.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERAS
Wall Street analysts forecast ERAS stock price to fall
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 13.410
Low
2.00
Averages
5.50
High
11.00
Current: 13.410
Low
2.00
Averages
5.50
High
11.00
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Erasca Faces Class Action Lawsuit, Stock Plummets 45%
- Class Action Filed: Block & Leviton LLP has initiated a class action lawsuit against Erasca, Inc. on behalf of individual investors, alleging violations of federal securities laws due to false and misleading statements that have undermined investor confidence.
- Drug Candidate Issues: The lawsuit claims that Erasca falsely promoted its lead oncology drug ERAS-0015 as a 'best-in-class' therapy between January 2025 and April 2026, failing to disclose improper comparisons with competitors that exposed the company to potential patent and trade secret disputes.
- Stock Price Plummet: Following the disclosure of patent infringement accusations from Revolution Medicines on April 27, 2026, Erasca's stock price fell over 45%, reflecting significant market concerns regarding the company's future prospects.
- Investor Rights Protection: The lawsuit seeks damages for investors who purchased Erasca stock during the class period, allowing them to apply as lead plaintiffs by August 10, 2026, to protect their interests in the ongoing legal proceedings.
See More
Erasca Faces Legal Challenge Over IP Claims
- Stock Price Plunge: Erasca, Inc. (NASDAQ:ERAS) saw its shares plummet by $9.25 (-48%) on April 28, 2026, after facing a legal challenge from competitor Revolution Medicines regarding intellectual property claims, resulting in a loss of over $2.8 billion in market capitalization in just one day, indicating a severe erosion of market confidence in its lead product ERAS-0015.
- Legal Investigation Launched: The national shareholder rights law firm Hagens Berman has initiated an investigation into whether Erasca misled investors about the viability of its ERAS-0015 intellectual property, urging affected investors to come forward, suggesting potential broader legal ramifications for the company.
- Competitor Allegations: Revolution Medicines has accused Erasca of infringing on its patents with ERAS-0015 and demanded an immediate halt to its sale and importation in the U.S., highlighting the intensifying competition in the oncology sector and posing significant challenges to Erasca's market position.
- Investor Confidence Eroded: Despite Erasca's assurances regarding its intellectual property protection on March 12, 2026, the subsequent legal challenge has cast doubt on these claims, potentially leading to diminished investor confidence that could adversely affect the company's future financing and market performance.
See More
Erasca Faces Legal Challenge Over Intellectual Property Claims
- Stock Price Plunge: Erasca, Inc. saw its shares plummet by $9.25 (-48%) on April 28, 2026, following the announcement of a legal challenge to its intellectual property, resulting in a loss of over $2.8 billion in market capitalization in a single day, indicating a severe erosion of investor confidence in its lead product ERAS-0015.
- Legal Challenge Context: Competitor Revolution Medicines has initiated a legal challenge against Erasca's ERAS-0015, claiming patent infringement and demanding an immediate halt to sales in the U.S., which could have long-term implications for Erasca's market position and competitive strategy.
- Investor Investigation Launched: Hagens Berman law firm has opened an investigation into whether Erasca misled investors regarding the viability of its intellectual property, urging affected investors to come forward, which may further undermine investor confidence and lead to potential legal repercussions for the company.
- Uncertain Product Development Outlook: While ERAS-0015 is considered a potential
See More
Erasca Faces Investor Lawsuit Investigation
- Legal Investigation Initiated: Bragar Eagel & Squire, P.C. is investigating Erasca for potential violations of federal securities laws or other unlawful business practices, indicating significant legal risks for the company.
- Significant Stock Price Drop: On April 28, 2026, Erasca's stock plummeted by $9.25, approximately 48%, from $19.15 to $9.90, severely impacting investor confidence and raising concerns about the company's stability.
- Investor Rights Protection: The law firm encourages all investors who suffered losses in Erasca to reach out, highlighting the potential for a class-action lawsuit, which could further exacerbate market fears regarding the company's future.
- Recommended Next Steps: Shareholders with information or questions are offered free consultations, demonstrating a commitment to investor rights while potentially affecting Erasca's reputation and market performance.
See More
RTW Investments Increases Stake in Erasca
- Increased Holdings: RTW Investments acquired 16,010,524 shares of Erasca in Q1 2026, with an estimated transaction value of $189.23 million, indicating strong confidence in the company's future prospects.
- Market Value Growth: The quarter-end value of Erasca's holdings reached $261.42 million, reflecting an increase of $260.88 million from the previous quarter, driven by both share price appreciation and additional purchases.
- R&D Progress: Erasca's lead program, ERAS-0015, has shown promising early responses in patients with KRAS-driven lung and pancreatic cancers, with the CEO highlighting its potential as a future
See More
RTW Investments Increases Stake in Erasca
- Stake Increase: RTW Investments disclosed in a May 15, 2026 SEC filing that it acquired 16,010,524 shares of Erasca, valued at approximately $189.23 million, indicating strong confidence in the company's prospects.
- Value Growth: As of March 31, 2026, RTW's total stake in Erasca reached $261.42 million, an increase of $260.88 million from the previous quarter, reflecting optimistic market expectations for Erasca's future developments.
- Outstanding Market Performance: Erasca's shares are priced at $12.84, having surged nearly 800% over the past year, significantly outperforming the S&P 500's 28% increase, showcasing growing investor confidence in its research pipeline.
- Strong Financial Position: As of March 2026, Erasca had $408.5 million in cash and marketable securities, expected to fund operations into the second half of 2028, enhancing its research capabilities and competitive position in cancer treatment.
See More
Erasca Faces Class Action Lawsuit, Stock Plummets 45%
- Class Action Filed: Block & Leviton LLP has initiated a class action lawsuit against Erasca, Inc. on behalf of individual investors, alleging violations of federal securities laws due to false and misleading statements that have undermined investor confidence.
- Drug Candidate Issues: The lawsuit claims that Erasca falsely promoted its lead oncology drug ERAS-0015 as a 'best-in-class' therapy between January 2025 and April 2026, failing to disclose improper comparisons with competitors that exposed the company to potential patent and trade secret disputes.
- Stock Price Plummet: Following the disclosure of patent infringement accusations from Revolution Medicines on April 27, 2026, Erasca's stock price fell over 45%, reflecting significant market concerns regarding the company's future prospects.
- Investor Rights Protection: The lawsuit seeks damages for investors who purchased Erasca stock during the class period, allowing them to apply as lead plaintiffs by August 10, 2026, to protect their interests in the ongoing legal proceedings.
See More
Erasca Faces Legal Challenge Over IP Claims
- Stock Price Plunge: Erasca, Inc. (NASDAQ:ERAS) saw its shares plummet by $9.25 (-48%) on April 28, 2026, after facing a legal challenge from competitor Revolution Medicines regarding intellectual property claims, resulting in a loss of over $2.8 billion in market capitalization in just one day, indicating a severe erosion of market confidence in its lead product ERAS-0015.
- Legal Investigation Launched: The national shareholder rights law firm Hagens Berman has initiated an investigation into whether Erasca misled investors about the viability of its ERAS-0015 intellectual property, urging affected investors to come forward, suggesting potential broader legal ramifications for the company.
- Competitor Allegations: Revolution Medicines has accused Erasca of infringing on its patents with ERAS-0015 and demanded an immediate halt to its sale and importation in the U.S., highlighting the intensifying competition in the oncology sector and posing significant challenges to Erasca's market position.
- Investor Confidence Eroded: Despite Erasca's assurances regarding its intellectual property protection on March 12, 2026, the subsequent legal challenge has cast doubt on these claims, potentially leading to diminished investor confidence that could adversely affect the company's future financing and market performance.
See More
Erasca Faces Legal Challenge Over Intellectual Property Claims
- Stock Price Plunge: Erasca, Inc. saw its shares plummet by $9.25 (-48%) on April 28, 2026, following the announcement of a legal challenge to its intellectual property, resulting in a loss of over $2.8 billion in market capitalization in a single day, indicating a severe erosion of investor confidence in its lead product ERAS-0015.
- Legal Challenge Context: Competitor Revolution Medicines has initiated a legal challenge against Erasca's ERAS-0015, claiming patent infringement and demanding an immediate halt to sales in the U.S., which could have long-term implications for Erasca's market position and competitive strategy.
- Investor Investigation Launched: Hagens Berman law firm has opened an investigation into whether Erasca misled investors regarding the viability of its intellectual property, urging affected investors to come forward, which may further undermine investor confidence and lead to potential legal repercussions for the company.
- Uncertain Product Development Outlook: While ERAS-0015 is considered a potential
See More
Erasca Faces Investor Lawsuit Investigation
- Legal Investigation Initiated: Bragar Eagel & Squire, P.C. is investigating Erasca for potential violations of federal securities laws or other unlawful business practices, indicating significant legal risks for the company.
- Significant Stock Price Drop: On April 28, 2026, Erasca's stock plummeted by $9.25, approximately 48%, from $19.15 to $9.90, severely impacting investor confidence and raising concerns about the company's stability.
- Investor Rights Protection: The law firm encourages all investors who suffered losses in Erasca to reach out, highlighting the potential for a class-action lawsuit, which could further exacerbate market fears regarding the company's future.
- Recommended Next Steps: Shareholders with information or questions are offered free consultations, demonstrating a commitment to investor rights while potentially affecting Erasca's reputation and market performance.
See More
RTW Investments Increases Stake in Erasca
- Increased Holdings: RTW Investments acquired 16,010,524 shares of Erasca in Q1 2026, with an estimated transaction value of $189.23 million, indicating strong confidence in the company's future prospects.
- Market Value Growth: The quarter-end value of Erasca's holdings reached $261.42 million, reflecting an increase of $260.88 million from the previous quarter, driven by both share price appreciation and additional purchases.
- R&D Progress: Erasca's lead program, ERAS-0015, has shown promising early responses in patients with KRAS-driven lung and pancreatic cancers, with the CEO highlighting its potential as a future
See More
RTW Investments Increases Stake in Erasca
- Stake Increase: RTW Investments disclosed in a May 15, 2026 SEC filing that it acquired 16,010,524 shares of Erasca, valued at approximately $189.23 million, indicating strong confidence in the company's prospects.
- Value Growth: As of March 31, 2026, RTW's total stake in Erasca reached $261.42 million, an increase of $260.88 million from the previous quarter, reflecting optimistic market expectations for Erasca's future developments.
- Outstanding Market Performance: Erasca's shares are priced at $12.84, having surged nearly 800% over the past year, significantly outperforming the S&P 500's 28% increase, showcasing growing investor confidence in its research pipeline.
- Strong Financial Position: As of March 2026, Erasca had $408.5 million in cash and marketable securities, expected to fund operations into the second half of 2028, enhancing its research capabilities and competitive position in cancer treatment.
See More
